Genetic features of platinum-resistant ovarian cancer patients

The authors try to decide a problem of ovarian cancer resistance to platinum drugs by the way of correlation finding between platinum-resistance of tumor and presence of gene mutations in the patient.It was shown a variety of options for BRCA gene mutations in patients with ovarian cancer:BRCA 1(185delAG)-64.2%,BRCA 1(5382 insC)-55.7%,and BRCA 2(6174delT)-53.8%.Authors discovered a significant positive correlation between carriage of mutations in the BRCA genes 1/2 and the sensitivity of malignant ovarian tumors to chemotherapy with platinum.Mutations in these genes occurred significantly more often in patients with platinum-sensitive ovarian cancer.

The authors try to decide a problem of ovarian cancer resistance to platinum drugs by the way of correlation finding between platinum-resistance of tumor and presence of gene mutations in the patient. It was shown a variety of options for BRCA gene mutations in patients with ovarian cancer： BRCA 1 （185de- 1AG）-64.2%, BRCA 1 （5382 insC）-55.7%, and BRCA 2 （6174delT）-53.8%. Authors discovered a significant positive correlation between carriage of mutations in the BRCA genes 1/2 and the sensitivity of malignant ovarian tumors to chemotherapy with platinum. Mutations in these genes occurred significantly more often in patients with platinum-sensitive ovarian cancer.